Terri S. Armstrong

Neuro-Oncology Branch
The Center for Cancer Research
United States of America

Scientist Genetics
Biography

Dr. Armstrong obtained her master's in oncology from The Ohio State University and her Ph.D. from the University of Texas Health Science Center. She has worked iin the field of neuro-oncology since 1992, and has held faculty positions at Emory University, M.D. Anderson Cancer Center, and the University of Texas Health Science Center School of Nursing, where she held the school’s prestigious Dunn Distinguished Professorship in Oncology Nursing. She has maintained a clinical practice in neuro-oncology as well as research faculty positions with a focus on clinical outcomes assessment and exploring clinical and biologic predictors of toxicity and symptoms. She has received numerous research grants from philanthropy, professional associations, and was awarded an NIH R01 grant developing prediction models of toxicity. She has published 100 manuscripts in peer-reviewed journals and over 15 book chapters on the care of patients with central nervous system tumors in addition to presenting on a regional, national and international level. She is currently Vice President of the Society for Neuro-Oncology and Quality of Life representative and chair on several studies in cooperative groups including Alliance Oncology and the NRG Oncology Research Group. 

Research Intrest

Cancer Biology, Clinical Research, Genetics and Genomics, Health Disparities, Social and Behavioral Sciences 

List of Publications
Armstrong TS, Vera-Bolanos E, Acquaye AA, Gilbert MR, Mendoza T (2016) The symptom burden of primary brain tumors: evidence for a core set of tumor- and treatment-related symptoms. Neuro Oncol. 18: 252-260.
Armstrong TS, Vera-Bolanos E, Gning I, Acquaye A, Gilbert MR, et al. (2011) The impact of symptom interference using the MD Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT) on prediction of recurrence in primary brain tumor patients. Cancer. 117: 3222-3228.
Armstrong TS, Cao Y, Scheurer ME, Vera-Bolaños E, Manning R, et al. (2009) Risk analysis of severe myelotoxicity with temozolomide: the effects of clinical and genetic factors. Neuro Oncol. 11: 825-832.
Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, et al. (2014) A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 370: 699-708.
Armstrong TS, Wefel JS, Wang M, Gilbert MR, Won M, et al. (2013) Net clinical benefit analysis of radiation therapy oncology group 0525: a phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma. J Clin Oncol. 31: 4076-4084.